{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:46:56Z","timestamp":1794412016484,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["1120027"],"award-info":[{"award-number":["1120027"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For loco-regionally advanced, but transorally resectable oropharyngeal cancer (OPSCC), the current standard of care includes surgical resection and risk-adapted adjuvant (chemo) radiotherapy, or definite chemoradiation with or without salvage surgery. While transoral surgery for OPSCC has increased over the last decade for example in the United States due to transoral robotic surgery, this treatment approach has a long history in Germany. In contrast to Anglo-Saxon countries, transoral surgical approaches have been used frequently in Germany to treat patients with oro-, hypopharyngeal and laryngeal cancer. Transoral laser microsurgery (TLM) has had a long tradition since its introduction in the early 70s. To date, the different therapeutic approaches to transorally resectable OPSCC have not been directly compared to each other in a randomized trial concerning disease control and survival. The goal of this study is to compare initial transoral surgery to definitive chemoradiation for resectable OPSCC, especially with regards to local and regional control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TopROC is a prospective, two-arm, open label, multicenter, randomized, and controlled comparative effectiveness study. Eligible patients are \u226518\u2009years old with treatment-na\u00efve, histologically proven OPSCC (T1, N2a-c, M0; T2, N1\u20132c, M0; T3, N0-2c, M0 UICC vers. 7) which are amenable to transoral resection. Two hundred eighty patients will be randomly assigned (1:1) to surgical treatment (arm A) or chemoradiation (arm B). Standard of care treatment will be performed according to daily routine practice. Arm A consists of transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy. Patients treated in arm B receive standard chemoradiation, residual tumor may be subject to salvage surgery. Follow-up visits for 3\u2009years are planned. Primary endpoint is time to local or locoregional failure (LRF). Secondary endpoints include overall and disease free survival, toxicity, and patient reported outcomes. Approximately 20 centers will be involved in Germany. This trial is supported by the German Cancer Aid and accompanied by a scientific support program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will shed light on an urgently-needed randomized comparison of the strategy of primary chemoradiation vs. primary surgical approach. As a comparative effectiveness trial, it is designed to provide data based on two established regimens in daily clinical routine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03691441?term=toproc&amp;draw=2&amp;rank=1\">NCT03691441<\/jats:ext-link> Registered 1 October 2018 - Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07127-2","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:07:53Z","timestamp":1596010073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC)"],"prefix":"10.1186","volume":"20","author":[{"given":"Lara","family":"Bu\u00dfmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Laban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Wittekindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Stromberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Tribius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"M\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Stephan","family":"Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Peter","family":"Klussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Budach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Muenscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-8237","authenticated-orcid":false,"given":"Chia-Jung","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"issue":"6","key":"7127_CR1","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.hoc.2008.10.002","volume":"22","author":"L Licitra","year":"2008","unstructured":"Licitra L, Zigon G, Gatta G, S\u00e1nchez M-J, Berrino F. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am. 2008;22(6):1143\u201353.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"7127_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","volume":"26","author":"AK Chaturvedi","year":"2008","unstructured":"Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"7127_CR3","first-page":"616","volume":"29","author":"A Lewis","year":"2015","unstructured":"Lewis A, Kang R, Levine A, Maghami E. The new face of head and neck cancer: the HPV epidemic. Oncology (Williston Park). 2015;29(9):616\u201326.","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"7127_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-19-0098","volume":"12","author":"C Wittekindt","year":"2019","unstructured":"Wittekindt C, Wagner S, Bushnak A, Prigge ES, von Knebel DM, Wurdemann N, Bernhardt K, Pons-Kuhnemann J, Maulbecker-Armstrong C, Klussmann JP. Increasing incidence rates of oropharyngeal squamous cell carcinoma in Germany and significance of disease burden attributed to human papillomavirus. Cancer Prev Res (Phila). 2019;12(6):375\u201382.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"4","key":"7127_CR5","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1002\/cam4.2039","volume":"8","author":"M Reuschenbach","year":"2019","unstructured":"Reuschenbach M, Tinhofer I, Wittekindt C, Wagner S, Klussmann JP. A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med. 2019;8(4):1908\u201318.","journal-title":"Cancer Med"},{"issue":"4","key":"7127_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ejca.2014.12.018","volume":"51","author":"I Tinhofer","year":"2015","unstructured":"Tinhofer I, Johrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, Stenzinger A, Stromberger C, Klinghammer K, Becker ET, et al. Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer. 2015;51(4):514\u201321.","journal-title":"Eur J Cancer"},{"issue":"8","key":"7127_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/ijc.22355","volume":"120","author":"N Reimers","year":"2007","unstructured":"Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas-Lichius O, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120(8):1731\u20138.","journal-title":"Int J Cancer"},{"issue":"1","key":"7127_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3892\/ijo.2014.2697","volume":"46","author":"ES Quabius","year":"2015","unstructured":"Quabius ES, Haag J, Kuhnel A, Henry H, Hoffmann AS, Gorogh T, Hedderich J, Evert M, Beule AG, Maune S, et al. Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany. Int J Oncol. 2015;46(1):414\u201322.","journal-title":"Int J Oncol"},{"issue":"1","key":"7127_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"7127_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/bjc.2017.132","volume":"116","author":"S Wagner","year":"2017","unstructured":"Wagner S, Wittekindt C, Sharma SJ, Wuerdemann N, Juttner T, Reuschenbach M, Prigge ES, von Knebel DM, Gattenlohner S, Burkhardt E, et al. Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer. Br J Cancer. 2017;116(12):1604\u201311.","journal-title":"Br J Cancer"},{"issue":"5","key":"7127_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","volume":"16","author":"AD Colevas","year":"2018","unstructured":"Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Cancer Netw. 2018;16(5):479\u201390.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"Suppl 5","key":"7127_CR12","doi-asserted-by":"publisher","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","volume":"21","author":"V Gregoire","year":"2010","unstructured":"Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v184\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"7127_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MOO.0b013e3283509735","volume":"20","author":"H Mehanna","year":"2012","unstructured":"Mehanna H, Olaleye O, Licitra L. Oropharyngeal cancer - is it time to change management according to human papilloma virus status? Curr Opin Otolaryngol Head Neck Surg. 2012;20(2):120\u20134.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"10166","key":"7127_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51\u201360.","journal-title":"Lancet"},{"issue":"10166","key":"7127_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40\u201350.","journal-title":"Lancet"},{"issue":"6","key":"7127_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00405-007-0280-6","volume":"264","author":"MC Jackel","year":"2007","unstructured":"Jackel MC, Martin A, Steiner W. Twenty-five years experience with laser surgery for head and neck tumors: report of an international symposium, Gottingen, Germany, 2005. Eur Arch Otorhinolaryngol. 2007;264(6):577\u201385.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"9","key":"7127_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/000348949910800901","volume":"108","author":"HH Rudert","year":"1999","unstructured":"Rudert HH, Werner JA, Hoft S. Transoral carbon dioxide laser resection of supraglottic carcinoma. Ann Otol Rhinol Laryngol. 1999;108(9):819\u201327.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"7127_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1067\/mhn.2001.111597","volume":"124","author":"W Steiner","year":"2001","unstructured":"Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg. 2001;124(1):58\u201367.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"7127_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00106-013-2678-3","volume":"61","author":"BB Lorincz","year":"2013","unstructured":"Lorincz BB, Laban S, Knecht R. The development of TORS in Europe. HNO. 2013;61(4):294\u20139.","journal-title":"HNO"},{"key":"7127_CR20","doi-asserted-by":"publisher","unstructured":"Lorincz BB, Mockelmann N, Busch CJ, Knecht R. Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck. 2015;37(11):1618\u201324. https:\/\/doi.org\/10.1002\/hed.23809. Epub 2014 Aug 28.","DOI":"10.1002\/hed.23809"},{"issue":"10","key":"7127_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","volume":"20","author":"AC Nichols","year":"2019","unstructured":"Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349\u201359.","journal-title":"Lancet Oncol"},{"key":"7127_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00103-014-2106-1","volume":"58","author":"K Wegscheider","year":"2015","unstructured":"Wegscheider K, Drabik A, Bleich C, Schulz H. Benefit assessment in health services research and epidemiology. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2015;58:298.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"issue":"10","key":"7127_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2165\/11536160-000000000-00000","volume":"28","author":"CD Mullins","year":"2010","unstructured":"Mullins CD, Whicher D, Reese ES, Tunis S. Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. PharmacoEconomics. 2010;28(10):969\u201376.","journal-title":"PharmacoEconomics"},{"issue":"9","key":"7127_CR24","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1245\/s10434-014-3702-x","volume":"21","author":"A Ebrahimi","year":"2014","unstructured":"Ebrahimi A, Clark JR, Amit M, Yen TC, Liao CT, Kowalski LP, Kreppel M, Cernea CR, Bachar G, Villaret AB, et al. Minimum nodal yield in oral squamous cell carcinoma: defining the standard of care in a multicenter international pooled validation study. Ann Surg Oncol. 2014;21(9):3049\u201355.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7127_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","volume":"110","author":"V Gregoire","year":"2014","unstructured":"Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110(1):172\u201381.","journal-title":"Radiother Oncol"},{"issue":"2","key":"7127_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0360-3016(02)03940-8","volume":"55","author":"KS Chao","year":"2003","unstructured":"Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55(2):312\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"7127_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ijrobp.2009.03.065","volume":"76","author":"P Ghadjar","year":"2010","unstructured":"Ghadjar P, Schreiber-Facklam H, Grater R, Evers C, Simcock M, Geretschlager A, Blumstein NM, Zbaren P, Zimmer Y, Wilkens L, et al. Quantitative analysis of extracapsular extension of metastatic lymph nodes and its significance in radiotherapy planning in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;76(4):1127\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"7127_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ijrobp.2005.08.020","volume":"64","author":"S Apisarnthanarax","year":"2006","unstructured":"Apisarnthanarax S, Elliott DD, El-Naggar AK, Asper JA, Blanco A, Ang KK, Garden AS, Morrison WH, Rosenthal D, Weber RS, et al. Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes. Int J Radiat Oncol Biol Phys. 2006;64(3):678\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"7127_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2009.01.037","volume":"76","author":"JJ Caudell","year":"2010","unstructured":"Caudell JJ, Meredith RF, Spencer SA, Keene KS, Dobelbower MC, Bonner JA. Margin on gross tumor volume and risk of local recurrence in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;76(1):164\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"7127_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hed.20279","volume":"27","author":"J Bernier","year":"2005","unstructured":"Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843\u201350.","journal-title":"Head Neck"},{"issue":"2","key":"7127_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/1078-0432.CCR-13-1101","volume":"20","author":"A Grobe","year":"2014","unstructured":"Grobe A, Blessmann M, Hanken H, Friedrich RE, Schon G, Wikner J, Effenberger KE, Kluwe L, Heiland M, Pantel K, et al. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 2014;20(2):425\u201333.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7127_CR32","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/annonc\/mdu271","volume":"25","author":"I Tinhofer","year":"2014","unstructured":"Tinhofer I, Konschak R, Stromberger C, Raguse JD, Dreyer JH, Johrens K, Keilholz U, Budach V. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25(10):2042\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"7127_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1148\/radiol.11101821","volume":"263","author":"HC Thoeny","year":"2012","unstructured":"Thoeny HC, De Keyzer F, King AD. Diffusion-weighted MR imaging in the head and neck. Radiology. 2012;263(1):19\u201332.","journal-title":"Radiology"},{"issue":"9","key":"7127_CR34","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00330-010-1769-8","volume":"20","author":"AD King","year":"2010","unstructured":"King AD, Mo FK, Yu KH, Yeung DK, Zhou H, Bhatia KS, Tse GM, Vlantis AC, Wong JK, Ahuja AT. Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol. 2010;20(9):2213\u201320.","journal-title":"Eur Radiol"},{"issue":"7","key":"7127_CR35","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00330-010-1734-6","volume":"20","author":"V Vandecaveye","year":"2010","unstructured":"Vandecaveye V, Dirix P, De Keyzer F, de Beeck KO, Vander Poorten V, Roebben I, Nuyts S, Hermans R. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol. 2010;20(7):1703\u201314.","journal-title":"Eur Radiol"},{"issue":"3","key":"7127_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1078-0432.CCR-08-1287","volume":"15","author":"S Kim","year":"2009","unstructured":"Kim S, Loevner L, Quon H, Sherman E, Weinstein G, Kilger A, Poptani H. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res. 2009;15(3):986\u201394.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7127_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1148\/radiol.2511080128","volume":"251","author":"V Vandecaveye","year":"2009","unstructured":"Vandecaveye V, De Keyzer F, Vander Poorten V, Dirix P, Verbeken E, Nuyts S, Hermans R. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology. 2009;251(1):134\u201346.","journal-title":"Radiology"},{"issue":"7","key":"7127_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00106-016-0191-1","volume":"64","author":"T Kurzweg","year":"2016","unstructured":"Kurzweg T, Kimmeyer J, Knecht R, Hoffmann TK, Busch CJ, Lorincz BB, Schuler PJ, Laban S. Curative treatment of head and neck squamous cell carcinoma : organ preservation strategies in clinical routine in German-speaking countries. Hno. 2016;64(7):501\u20137.","journal-title":"Hno"},{"issue":"15_suppl","key":"7127_CR39","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1200\/jco.2010.28.15_suppl.5507","volume":"28","author":"K Ang","year":"2010","unstructured":"Ang K, Zhang Q, Wheeler RH, Rosenthal DI, Nguyen-Tan F, Kim H, Lu C, Axelrod RS, Silverman CI, Weber RS. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome. J Clin Oncol. 2010;28(15_suppl):5507.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"7127_CR40","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1200\/jco.2012.30.15_suppl.5512","volume":"30","author":"V Budach","year":"2012","unstructured":"Budach V, Cho C-H, Sedlmaier B, Wittlinger M, Iro H, Engenhart-Cabillic R, Hautmann M, Strutz J, Flentje M, Hueltenschmidt B, et al. Five years\u2019 results of the German ARO 04\u201301 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum\/5-FU versus mitomycin C\/5-FU in stage IV head and neck cancer. J Clin Oncol. 2012;30(15_suppl):5512.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"7127_CR41","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1200\/jco.2012.30.15_suppl.5500","volume":"30","author":"EEW Cohen","year":"2012","unstructured":"Cohen EEW, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2\/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2012;30(15_suppl):5500.","journal-title":"J Clin Oncol"},{"issue":"18_suppl","key":"7127_CR42","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1200\/jco.2006.24.18_suppl.5517","volume":"24","author":"AA Forastiere","year":"2006","unstructured":"Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, Trotti A, Ridge J, Ensley J, Chao C, Cooper J. Long-term results of Intergroup RTOG 91\u201311: A phase III trial to preserve the larynx\u2014Induction cisplatin\/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol. 2006;24(18_suppl):5517.","journal-title":"J Clin Oncol"},{"issue":"22","key":"7127_CR43","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal Cancer. N Engl J Med. 2003;349(22):2091\u20138.","journal-title":"N Engl J Med"},{"issue":"7","key":"7127_CR44","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","volume":"31","author":"AA Forastiere","year":"2013","unstructured":"Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845\u201352.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7127_CR45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257\u201364.","journal-title":"Lancet Oncol"},{"issue":"29","key":"7127_CR46","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1200\/JCO.2015.62.3157","volume":"33","author":"FC Holsinger","year":"2015","unstructured":"Holsinger FC, Ferris RL. Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment Paradigm of oropharynx cancer: robotics, lasers, and clinical trials. J Clin Oncol. 2015;33(29):3285\u201392.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7127_CR47","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/cncr.22963","volume":"110","author":"EM Sturgis","year":"2007","unstructured":"Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110(7):1429\u201335.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07127-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07127-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:15:04Z","timestamp":1650536104000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07127-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7127"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07127-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial has been approved by the ethics committee of the \u00c4rztekammer in Hamburg (PVN5578). It is conducted in agreement with the ICH Harmonized Tripartite Guideline on Good Clinical Practice, valid since 17.01.1997, the Declaration of Helsinki (in its current version) and the respective national laws (in its current version).Informed consent, obtained from all patients, will be verbal and in written form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"701"}}